Head to Head Review: Caladrius Biosciences (CLBS) and The Competition
Caladrius Biosciences (NASDAQ: CLBS) is one of 182 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Caladrius Biosciences to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, profitability and earnings.
Institutional & Insider Ownership
6.4% of Caladrius Biosciences shares are owned by institutional investors. Comparatively, 50.0% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.1% of Caladrius Biosciences shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Caladrius Biosciences has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Caladrius Biosciences’ rivals have a beta of 1.54, meaning that their average share price is 54% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Caladrius Biosciences and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Caladrius Biosciences Competitors||539||2420||6623||128||2.65|
Caladrius Biosciences currently has a consensus price target of $7.00, suggesting a potential upside of 105.88%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 33.01%. Given Caladrius Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Caladrius Biosciences is more favorable than its rivals.
Valuation and Earnings
This table compares Caladrius Biosciences and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Caladrius Biosciences||$35.28 million||-$32.65 million||1.61|
|Caladrius Biosciences Competitors||$217.29 million||-$39.39 million||-102.20|
Caladrius Biosciences’ rivals have higher revenue, but lower earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This table compares Caladrius Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Caladrius Biosciences Competitors||-4,453.84%||-586.82%||-44.85%|
Caladrius Biosciences beats its rivals on 8 of the 12 factors compared.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.